Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00952484 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Asfotase Alfa in Juvenile Patients With Hypophosphatasia (HPP)
A Phase 2 study, sponsored by Alexion Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT00952484 is a Phase 2 study that has completed, run by Alexion Pharmaceuticals. The registered enrollment target is 13 participants.
The verdict
NCT00952484, a Phase 2 study, has completed, sponsored by Alexion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
This clinical trial studied the safety and efficacy of asfotase alfa in children with HPP compared to a historical control group.
Interventions
- BIOLOGICAL asfotase alfa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2009-09 |
| Est. Completion | 2010-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00952484
The ClinicalTrials.gov registry entry for NCT00952484 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which asfotase alfa is the first listed.
NCT00952484 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00952484 about?
NCT00952484 is a clinical study titled "Safety and Efficacy of Asfotase Alfa in Juvenile Patients With Hypophosphatasia (HPP)". This clinical trial studied the safety and efficacy of asfotase alfa in children with HPP compared to a historical control group.
What is the current status of trial NCT00952484?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2009-09. Estimated completion is 2010-07.
What interventions are being tested in trial NCT00952484?
The interventions under investigation include: asfotase alfa (BIOLOGICAL).
Who is sponsoring clinical trial NCT00952484?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.